hiPS43
EPFLi001-A
General
Cell Line |
|
hPSCreg name | EPFLi001-A |
Cite as: | EPFLi001-A (RRID:CVCL_VD34) |
Alternative name(s) |
hiPS43
|
Cell line type | Human induced pluripotent stem cell (hiPSC) |
Similar lines | No similar lines found. |
Last update | 22nd May 2019 |
User feedback | |
Provider |
|
Generator | Swiss Federal Institute of Technology (EPFL) |
Distributors | |
External Databases |
|
BioSamples | SAMEA104012163 |
Cellosaurus | CVCL_VD34 |
Wikidata | Q54832356 |
General Information |
|
Publications | |
* Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
Donor Information
General Donor Information |
|
Sex | male |
Phenotype and Disease related information (Donor) |
|
Diseases | No disease was diagnosed.
|
Karyotyping (Donor) |
|
Has the donor karyotype been analysed? |
Yes
46, XY
Karyotyping method:
G-Banding
|
External Databases (Donor) |
|
BioSamples | SAMEA104012324 |
Ethics
Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
Was the consent voluntarily given? | Yes |
Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No |
Please provide contact information of the holder of the original Donor Information Sheet. | Dr Yvan Vial (head of obstetrics), Centre Hospitalier Universitaire Vaudois (CHUV) |
Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
If you do not hold the Donor Consent Form, do you know who does? | No |
Please provide the contact information | |
Alternatives to consent | |
Alternative consent approval number | |
Is there other documentation provided to the donor for consenting purposes? | No |
Confirm that consent was obtained by a qualified professional | Yes |
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised |
Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
Does consent expressly prevent the derivation of pluripotent stem cells? | No |
Does consent pertain to a specific research project? | No |
Details on restriction to research project | |
Does consent permit unforeseen future research, without further consent? | No |
Does consent expressly prevent development of commercial products? | No |
Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? | No |
Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent permit research by | |
an academic institution? | Yes |
How may genetic information associated with the cell line be accessed? | No information |
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? | Yes |
Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? | Yes |
Please describe how access is provided: | |
Contact data, institution, or website: | |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
Name of accrediting authority involved? | |
Approval number | |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
Name of accrediting authority involved? | |
Approval number | |
Do you have obligations to third parties in regard to the use of the cell line? | No |
Please describe: | |
Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? | No |
Further constraints on use | |
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | |
Constraints for use or distribution |
hIPSC Derivation
General |
|
Source cell type (free text) | CD34+ hematopoietic stem cell |
Reprogramming method |
|
Vector type | Integrating |
Vector | Virus (Lentivirus) |
Is the used vector excisable? |
No |
Absence of reprogramming vector(s)? |
Unknown |
Reprogramming vectors silenced? |
Yes |
Vector free reprogramming |
|
Other |
|
Derived under xeno-free conditions |
Unknown |
Derived under GMP? |
Unknown |
Available as clinical grade? |
Unknown |
Culture Conditions
Medium |
mTeSR™ 1
|
Characterisation
Analysis of Undifferentiated Cells
Marker | Present | Absent |
mCpG | ||
OCT4 | X |
Transcriptome Characterisation
Differentiation Potency
Genotyping
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
Yes
46, XY
Karyotyping method:
G-Banding
|
Other Genotyping (Cell Line) |
Login to share your feedback, experiences or results with the research community.